SCHEMBL961750

SCHEMBL961750

N#CC(c1ccccc1)C1CCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 2/20 0.53
CHRNB4 P30926 1/20 0.50
CHRNA3 P32297 1/20 0.50
TRPA1 O75762 1/20 0.42
TSHR P16473 1/20 0.42
IDO1 P14902 4/20 0.42
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
PKM P14618 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HTR1E P28566 1/20 0.37
S1PR3 Q99500 1/20 0.37
CHRM2 P08172 3/20 0.36
CHRM1 P11229 3/20 0.36
CHRM4 P08173 2/20 0.36
CHRM3 P20309 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL961019 0.96 SLC6A3 (0.57) SLC6A3CHRNB4CHRNA3TRPA1TSHR
SCHEMBL959762 0.94 SLC6A3 (0.58) SLC6A3CHRNB4CHRNA3TRPA1TSHR
SCHEMBL13124077 0.94 SLC6A3 (0.58) SLC6A3CHRNB4CHRNA3TRPA1TSHR
SCHEMBL7355279 0.92 CHRNB4 (0.53) SLC6A3CHRNB4CHRNA3TRPA1TSHR
SCHEMBL17892330 0.85 SLC6A3 (0.55) SLC6A3CHRNB4CHRNA3IDO1GAA
SCHEMBL8191324 0.83 CHRNB4 (0.46) SLC6A3CHRNB4CHRNA3
SCHEMBL493477 0.83 CHRNB4 (0.46) SLC6A3CHRNB4CHRNA3TRPA1TSHR
Hydrochloric Acid SCHEMBL2586181 0.82 CHRNB4 (0.45) SLC6A3CHRNB4CHRNA3
SCHEMBL15179030 0.80 CYP3A4 (0.46) SLC6A3CHRNB4CHRNA3TRPA1TSHR
SCHEMBL8437518 0.78 CHRNB4 (0.49) CHRNB4CHRNA3TSHRL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008278-B2 Diarylmethyl and related compounds THERAVANCE, INC. (US) 2011-08-30 US disclosed
US-20110015152-A1 DIARYLMETHYL AND RELATED COMPOUNDS THERAVANCE, INC. (US) 2011-01-20 US disclosed
US-7829728-B2 Diarymethyl and related compounds THERAVANCE, INC. (US) 2010-11-09 US disclosed
US-20080114030-A1 Diarymethyl and related compounds THERAVANCE BIOPHARMA R&D IP, LLC 2008-05-15 US disclosed
US-7317102-B2 Diarylmethyl and related compounds THERAVANCE, INC. (US) 2008-01-08 US disclosed
US-20060287369-A1 Diarylmethyl and related compounds THERAVANCE BIOPHARMA R&D IP, LLC 2006-12-21 US disclosed
EP-1615881-A2 DIARYLMETHYL AND RELATED COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY Theravance, Inc. (US) 2006-01-18 EP disclosed
WO-2004089892-A2 DIARYLMETHYL AND RELATED COMPOUNDS HAVING BETA2 ANDRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY THERAVANCE, INC. (US) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114030-A1 Diarymethyl and related compounds ADRB2, ADRB1, ADRA2B SLC6A3 1585/4885CHRNB4 76/4885CHRNA3 55/4885
US-20060287369-A1 Diarylmethyl and related compounds ADRB2, ADRB1, ADRA2B SLC6A3 1409/4885CHRNB4 77/4885CHRNA3 46/4885
US-20110015152-A1 DIARYLMETHYL AND RELATED COMPOUNDS ADRB2, ADRB1, ADRA2B SLC6A3 1409/4885CHRNB4 77/4885CHRNA3 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.